Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vera Therapeutics Q2 2025 EPS $(1.20) Misses $(0.83) Estimate, Vera Reported $556.8M In Cash, Cash Equivalents, And Marketable Securities

Author: Benzinga Newsdesk | August 05, 2025 07:13am

Vera expects cash position to be sufficient to fund operations through potential approval and us commercial launch of Atacicept anticipated in 2026 and beyond

Posted In: VERA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist